To investigate the underlying causes and frequency of cancer in patients with hematospermia.
INTRODUCTION AND OBJECTIVES:
To investigate the underlying causes and frequency of cancer in patients with hematospermia.
METHODS: During a 15 years period, medical records of 161.258 men with >18 years old, presenting to Urology clinics, were screened retrospectively for the presence of hematospermia. Patients with external or iatrogenic trauma and genitourinary cancer history were excluded from the study. The study included 342 men who presented for hematospermia. Demographic data, history and physical examination results, all diagnostic tests, applied treatment, and follow-up information were recorded and evaluated in all patients.
RESULTS: Hematospermia was detected in 342 (0.21%) of the 161258 urological patients. The mean age of the patients was 45.05AE14.04 years (range: 16 to 85), and the median duration of hematospermia was 15 days (range 1 to 7200). Isolated hematospermia was found in 169 of 342 patients (49.4%). The remaining 173 patients (50.6%) were found to have one or more additional symptoms. Common additional symptoms consisted of lower urinary tract symptoms, dysuria, pelvic/perineal pain, painful ejaculation, and testicular pain. The etiologic causes of hematospermia were inflammation/infections in 169 (49.4%), idiopathic in 96 (28.1%), ductal obstruction and cysts in 34 (9.9%), systemic factors in 32 (9.4%), and genitourinary cancers were detected in only 11 patients (3.2%) as prostate cancer in 8 and testicular cancer in 3. On TRUS, 71.2% had visible one or more pathology that might be responsible for hematospermia. Of the patients, 306 (89.5)% had complete cure after medical therapy due to infections/ inflammations, surgery due to ductal obstruction and cysts, prostate and testicular cancer. However, 36 (10.5%) had persistent/recurrent hematospermia. Mean serum t/fPSA level was found as 11.88AE14.88/ 1.74AE0.95 ng/ml in the patients who were diagnosed prostate cancer with total PSA level of >4 ng/ml, except one. All of the patients who were diagnosed testicular cancer had testicular pain and/or swelling.
CONCLUSIONS: Hematospermia is seen frequently due to inflammatory or infectious causes, and is rarely associated with genitourinary cancer. Further diagnostic evaluation of hematospermia is not necessary in most patients. However, further diagnostic tools might be necessary to exclude urogenital malignancy in patients with specific findings of history and/or physical examination, non-response to empirical treatment, family history of testicular and/or prostate cancer, and associated symptoms such as lower urinary tract symptoms and scrotal pain and/or swelling.
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MP53-12 THERAPEUTIC EFFECT OF TADALAFIL IN THE CHRONIC PROSTATITIS
Norifumi Nishishita*, Kurashki, Japan; Shin Ohira, Kurashiki, Japan; Shigenobu Tone, Hiki-gun, Saitama, Japan; Ryoei Hara, Tomohiro Fujii, Shinya Uehara, Yoshiyuki Miyaji, Atsushi Nagai, Kurashiki, Japan INTRODUCTION AND OBJECTIVES: Tadalafil (PDE5 inhibitor) is indicated for the treatment of benign prostatic hyperplasia with lower urinary tract symptoms (BPH/LUTS) and erectile dysfunction (ED). In previous research, Tadalafil shows anti-inflammatory action in the prostate. The evidence-based data for the treatment of Chronic prostatitis (CP) is lacking. We hypothesized that Tadalafil contribute to innovative therapy for the CP. To examine this hypothesis, we investigated anti-inflammatory effect of Tadalafil using all sorts of cytokines/chemokine in the CP model mice.
METHODS: Ten to twelve weeks old C57BL/6 male mice were used through the study. Prostate gland extracted from Wister rat were used as PAg (concentration: 10mg / PBS1ml). PAg 100mg / titer max adjuvant 100ml were injected into mice subcutaneously (shoulder and tail). After CP modeling, systemic organs were obtained from individual mice up to 12 weeks every week. In preliminary examination, we confirmed the validity of CP model using comprehensive cytokines/ chemokines assay in the systemic organs. Next, we administrated Tadalafil 25mg / pure water 50ml (oral) up to 12 weeks every day (control: pure water 50ml / day). Histological changes were microscopically examined and evaluated using HE staining. Inflammatory changes in the CP model of Tadalafil administrated mice were analyzed using comprehensive cytokines/chemokines assay for determining representative candidates. Biochemical and immunohistochemical changes were analyzed using representative candidates. Series of these experiments were duplicated at least.
RESULTS: Histological analysis showed that invasion of inflammatory cells and fibrosis of interstitial tissue were observed in the CP model of Tadalafil non-administrated mice compared with Tadalafil administrated mice. Prostatic structure in Tadalafil administrated mice were still maintained at week12 after PAg injection. Comprehensive cytokines/chemokines assay showed that significant decreased expression of ICAM-1 (only week1), M-CSF, IL-16, CCL2, CCL3, CXCL2, TREM-1 and TIMP-1 were observed in the CP model of Tadalafil administrated mice compared with that of t administrated Tadalafil non-administrated mice. Same results were obtained from biochemical and immunohistochemical analysis using separate quantitative assay and immunofluorescent staining.
CONCLUSIONS: Tadalafil contribute to suppression of macrophage-related inflammatory and fibrosis change of interstitial tissue. Therefore, Tadalafil is an effective therapy in the chronic prostatitis.
Source of Funding: none
MP53-13 EFFICACY OF TADALAFIL FOR TREATING CHRONIC PROSTATITIS/CHRONIC PELVIC PAIN SYNDROME IN PATIENTS WITHOUT ERECTILE DYSFUNCTION
Hyun Jun Park*, Sung Woo Park, Nam Cheol Park, Busan, Korea, Republic of INTRODUCTION AND OBJECTIVES: PDE5 inhibitors increase blood flow to the pelvic organs and improve lower urinary tract symptoms, so it is postulated that PDE5 inhibitors could be effective on treating chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). In this background, we investigated the efficacy of tadalafil for the treatment of CP/CPPS in patients without erectile dysfunction (ED).
METHODS: Eighty-six males with a National Institutes of Health (NIH) diagnosis of category III CP/CPPS, but who did not have ED, were randomized in single-blinded fashion to receive either levofloxacin (500 mg/day; group 1; 40 patients) or levofloxacin (500 mg/day) and tadalafil (5 mg/day; group 2; 46 patients) for 6 weeks. The International Prostate Symptom Score (IPSS), NIH chronic prostatitis symptom index (NIH-CPSI), and erectile function (EF) domain scores of the International Index of Erectile Dysfunction (IIEF) questionnaire were used to grade symptoms at baseline and 6 weeks later.
RESULTS: The mean ages of the two groups were 49.2AE6.7 and 48.3AE7.1 years, respectively. There were no significant differences between the groups in age, duration of the condition, IPSSs, NIH-CPSI scores, or IIEF-EF domain scores at baseline. Tadalafil significantly improved the mean change in the IPPS from baseline to 6 weeks (group 1; -1.1 vs. group 2; -4.2, p<0.05). Significant improvements were also evident in the IPSS voiding subscore (group 1; -0.7 vs. group 2; -3.1, p<0.05). Larger changes from the NIH-CPSI baseline Vol. 201, No. 4S, Supplement, Sunday, May 5, 2019 THE JOURNAL OF UROLOGY Ò e779
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